No abstract available.
Humans

PURPOSE: To evaluate the effect of 9 mm and 7 mm bilateral recession of the superior rectus muscle in patients with bilateral dissociated vertical deviation (DVD) who had a deviation difference between the non-fixing and fixing eyes of less than 8PD. METHODS: The subjects were chosen from the patients who visited our hospital for DVD between January 2001 and November 2003. We reviewed the surgical records of 19 patients who had undergone 9 mm recession of superior rectus muscle in the non-fixing eye and 7 mm in fixing eye, and who had been followed up for at least 6 months. RESULTS: A residual DVD less than 8PD was regarded as successful. The overall success rate was 73.7%. The success rate of 10~14PD preoperative deviation of the non-fixing eye was 80.0%, and that of 15~19PD preoperative deviation of the non-fixing eye was 75.0%. However, the success rate was 66.7% in recession for the deviation over 20PD. CONCLUSIONS: Bilateral recession of 9 mm and 7 mm of the superior rectus muscle was effective for bilateral DVD in which the deviation difference of the non-fixing eye and fixing eyes was less than 8PD.
Humans

The Beta-2-microglobulin is the part of light chain of human histocompatibility antigen (HLA). This protein can be observed in most of the human nucleated cells. Some of reports indicated that the Beta-2-microglobulin was lost completely or partially in the malignant or premalignant lesions. Observations on presence of Beta-2-microglobulin were made on 24 cases of malignant, premalignant and benign epithelial umors and 6 cases of normal or non-neoplastic epithelial lesions in the skin, using PAP method. The PAP method. 1) Normal epidermis and no-neoplastic cutaneous lesions (chronic non-specific dematitis, actinic change of skin with pseudoepitheliomatous hyperplasia) showed strong positive staining along the cutaneous epithelial cytoplasmic surface for Beta-2-microglobuin in all 6 cases. 2) Benign cutaneous tumors (keratoacanthoma, squamous cell papilloma and pigmented nevus) showed similar strong positive staining for Beta-2-microglobulin along the epithelial cell surface in 4 out 6 cases. Remaining 2 cases were out of 4 pigmented nevus, which showed weakly or pretty weakly staining. 3) Premalignant cutaneous lesions as solar keratosis showed generally weak positive staining along the epithelial cytoplasmic surface in all 4 cases. 4) Malignant cutaneous tumors (basal cell carcinoma, squamous cell carcinoma, Bowen's disease and malignant melanoma) showed mostly negative staining along the surface of epithelial cells for Beta-2-microglobulin, in 8 out of 14 cases. Remaining 6 cases showed slightly weak or patchy positive staining. As above observation, the presence of Beta-2-microglobulin in cutaneous epithelial lesions using PAP method could be indicated as one of good differential tool for histopathologic diagnosis in cutaneous malignant lesions.
Humans

Glycopyrrolate, a synthetic quarternary ammonium compound, has a similar pharmacologic property to that of scopolamine, a belladonna alkaloid. Since glycopyrrolate, a quarternary ammonium compound, dose not readily cross the blood brain barrier, it has less central effect than that of scopoiamine a tertiary-amine compound. The authors administered a small dose of scopolamine and glycopyrrolate to human volunteers, and examined the effect on the heart rate ofr both drugs. The results were as follows: 1) A small dose of scopolamine(0.1mg) showed significnat decrease in the heart rate. 2) A small dose of gylcopyrrolate(0.1mg) indeced little change in the heart rate. 3) A small dose of gylcopyrrolate(0.1mg), 10minutes after glycopyrrolate(0.1mg), showed marked increase in the heart rate. 4) A small dose of scopolamine(0.1mg), given 10 minutes after glycopyrrolate (0.1mg), showed tendency for decrease in heart kate. 5) A small dose of gylcopyrrolate(0.1mg), 10 minutes afterscopolamine(0.1mg), showed significant increases in the heart rate. 6) Scopolamine induced bradycardia was suppressed by an additional dose of glycopyrrolate and a preceding dose of glycopyrrolate.
Humans

No abstract available.
Humans

PURPOSE: To assess the usefulness and reliability of the IOL power calculation computer program ('POWER!'). METHODS: Calculation times and projected postoperative refractive values of 100 patients with 'POWER!' program were compared with those of the program mounted on the Humphrey R A/B scan system (model 820) by SRK-II and SRK/T formula. RESULTS: There was no significant difference between the projected postoperative refractive values of 'POWER!' program and Humphrey R A/B scan system (paired-t test, p>0.05). Calculation time of 'POWER!' was shorter than that of the program mounted on the Humphrey R A/B scan system incalculating more than 3 sets of IOL (paired-t test, P<0.05) and there was no internal calculation error (ztest, p>0.05). CONCLUSIONS: 'POWER!' is a useful and reliable program for IOL power calculation using SRK-II and SRK/T formula.
Humans

Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may be only marginal over existing treatments. Sometimes assigning patients to a placebo is unethical. In such circumstances, there has been increasing emphasis on the use of noninferiority trial designs. Noninferiority trials are more complex to design, conduct, and interpret than typical superiority trials. This paper reviews the concept of noninferiority trials and discusses some important issues related to them.
Humans

No abstract available.
Humans

BACKGROUND: Efforts to reduce the wastage of blood components are necessary because of the shortage of blood components. To find ways of reducing the blood component wastage, we monitored the trends and reasons for wastage and we analyzed this data. METHODS: We have investigated and analyzed the amount and reasons for wastage from 2003 to 2005 by reviewing the wastage statements, and the information on these wastage statements was classified according to several aspects. Ouestions about the reasons for wastage and the methods for reducing such wastage were created and these were widely distributed to the doctors and nurses working at Pusan University Hospital. The results of the survey were analyzed. RESULTS: The wastage rates of blood component from 2003 to 2005 had a tendency to slightly decline: 1.49% in 2003, 1.26% in 2004 and 1.23% in 2005. The most frequent reason for wastage was the improvement in the patient's condition and the second most frequent reason was death of the patient. The favorite answers for the question about the most likely reason for wastage were related to different aspects of medicine, and also to the improvement in the patient's condition (52.6%) and the death of patient (22.6%) for the aspect of blood management, the most frequent answers were overcharge (43.3%) and delay of blood returning (17.7%). The analysis of the pattern of wastage showed that only 5 departments were responsible for 71.5%~78.1% of the wastage. CONCLUSION: Systematic and active management of the transfusion process, along with intensive cooperation of clinicians, is needed to prevent a considerable amount of blood component wastage.
Humans

No abstract available.
Humans